Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jan 2022 10:07

RNS Number : 6502X
4d Pharma PLC
06 January 2022
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

4D PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Steven Oliveira and connected parties

City and country of registered office (if applicable)

225 Via Palacio

Palm Beach Gardens

FL 33418

USA

4. Full name of shareholder(s) (if different from 3.) v

Name

South Ocean Capital Management, LLC

South Ocean Capital, LLC

Nemean Asset Management, LLC

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

4 January 2022

6. Date on which issuer notified (DD/MM/YYYY):

5 January 2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

6.89

0

6.89

12,415,110

Position of previous notification (if

applicable)

7.69

0

7.69

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary Shares of £0.0025 each

 

12,415,110

0

6.89

0

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

South Ocean Capital Management, LLC

3.27

3.27

South Ocean Capital, LLC

0.34

0.34

Nemean Asset Management LLC

3.28

3.28

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional information xvi

 

Place of completion

FL, USA

Date of completion

5 January 2022

 

 

 

 

 

Notes

 

i Please note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link: https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only in this way will the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain by numbering each chain accordingly. Please see the below example:

Name of ultimate controlling person A (chain 1)

Name of controlled undertaking B

Name of controlled undertaking C

Name of ultimate controlling person A (chain 2)

Name of controlled undertaking B

Name of controlled undertaking D

Name of ultimate controlling person A (chain3)

Name of controlled undertaking E

Name of controlled undertaking F

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFIILEIRIIF
Date   Source Headline
21st Dec 20187:00 amRNSDirector/PDMR Shareholding
19th Dec 20187:00 amRNSDirector/PDMR Shareholding
13th Dec 20187:00 amRNSPDMR Dealings
12th Dec 20184:40 pmRNSSecond Price Monitoring Extn
12th Dec 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20187:00 amRNSTrading Statement
8th Nov 20187:00 amRNSClinical Update - Blautix Phase II study
8th Nov 20187:00 amGNW4D pharma plc Announces Clinical Update for Blautix Phase II Study
28th Sep 20187:00 amRNSInterim results
24th Sep 20187:00 amRNSClinical update and publication of studies
14th Aug 20187:00 amRNS4D asthma publication
30th Jul 20187:00 amRNSPublication - microbiota as HDAC inhibitors
27th Jun 20187:00 amRNS4D Presents at IHMC 2018
25th Jun 20184:40 pmRNSSecond Price Monitoring Extn
25th Jun 20184:35 pmRNSPrice Monitoring Extension
13th Jun 20187:00 amRNSMHRA and HPRA clear Blautix Phase II study
12th Jun 20184:51 pmRNSHolding(s) in Company
7th Jun 20187:00 amRNSClinical Collaboration Agreement
4th Jun 20187:00 amRNS4D Presents Phase Ib Clinical Data on Blautix
21st May 201812:08 pmRNSResult of AGM
21st May 20187:00 amRNSMRx0518 - Monotherapy trial approved
8th May 20187:00 amRNSClinical Update - Blautix IND
26th Apr 20187:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20187:00 amRNSFinal Results
21st Mar 20187:00 amRNSOncology candidate update
20th Feb 20187:00 amRNSAppointment of Joint Broker
28th Sep 20177:00 amRNSInterim results
5th Sep 201712:54 pmRNSHolding(s) in Company
24th Aug 20177:00 amRNSIssue of Equity
26th May 20171:59 pmRNSResult of AGM
17th May 20174:40 pmRNSSecond Price Monitoring Extn
17th May 20174:35 pmRNSPrice Monitoring Extension
3rd May 20177:00 amRNSAnnual Report and Notice of AGM
27th Apr 20177:00 amRNSFinal Results
18th Apr 20177:59 amRNSAppointment of Joint Broker
10th Mar 20174:37 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSClinical Update
13th Dec 20167:00 amRNSClinical Update
9th Nov 20164:40 pmRNSSecond Price Monitoring Extn
9th Nov 20164:35 pmRNSPrice Monitoring Extension
8th Nov 20164:40 pmRNSSecond Price Monitoring Extn
8th Nov 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20164:40 pmRNSSecond Price Monitoring Extn
19th Oct 20164:35 pmRNSPrice Monitoring Extension
30th Sep 20167:00 amRNSInterim results for the period ended 30 June 2016
27th Sep 201610:59 amRNSHolding(s) in Company
15th Sep 20164:40 pmRNSSecond Price Monitoring Extn
15th Sep 20164:35 pmRNSPrice Monitoring Extension
9th Sep 201611:58 amRNSHolding(s) in Company
22nd Aug 20167:00 amRNSClinical Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.